Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase

Bioorg Med Chem Lett. 2012 Jan 1;22(1):110-4. doi: 10.1016/j.bmcl.2011.11.061. Epub 2011 Nov 23.

Abstract

We report herein the design and synthesis of novel 4-aminoquinazoline derivatives based on the inhibitors of VEGFR-2 tyrosine kinases. The VEGFR-2 inhibitory activities of these newly synthesized compounds were also evaluated and compared with that of ZD6474. We found that most of target compounds had good inhibitory potency. In particular, compounds 1h, 1n and 1o were found to be 6, 2 and 2-fold more potent than the positive control ZD6474. The leading compound 1h also showed an in vivo activity against HepG2 human tumor xenograft model in BALB/c-nu mice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Chemistry, Pharmaceutical / methods*
  • Drug Design
  • Drug Screening Assays, Antitumor / methods
  • Enzyme Inhibitors / pharmacology
  • Hep G2 Cells
  • Humans
  • Inhibitory Concentration 50
  • Mice
  • Mice, Nude
  • Models, Chemical
  • Neoplasm Transplantation
  • Piperidines / pharmacology
  • Quinazolines / chemical synthesis
  • Quinazolines / pharmacology*
  • Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors*
  • Vascular Endothelial Growth Factor Receptor-2 / chemistry

Substances

  • 4-aminoquinazoline
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Piperidines
  • Quinazolines
  • Vascular Endothelial Growth Factor Receptor-2
  • vandetanib